drug regulation

The Trump Administration released a proposed rule Jan. 31 that could alter the way many drugs are priced and paid for among Medicare and Medicaid plans. The proposed regulation would eliminate the regulatory safe harbor for rebates as they exist today, said Rachel Sachs, an expert on drug policy and pricing at Washington University in St. Louis.

Recent scandals involving high-priced generic drugs should prompt us to consider price controls for pharmaceutical companies, says an expert on the health care industry at the School of Law at Washington University.

The pharmaceutical industry could be wasting more than $50 billion a year in manufacturing costs alone, costs that could translate in to lower prices or greater research and development – according to findings of the largest empirical study ever performed of pharmaceutical manufacturing and the Food and Drug Administration monitoring policies. More…